Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma

BACKGROUND: Multiple low-cost biosimilars of bevacizumab are now available but their clinical efficacy has never been compared against the original (innovator) molecule in glioblastoma. The aim of the current analysis is to compare the overall survival (OS) in recurrent/progressive glioblastoma pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Gunjesh, DSouza, Hollis, Menon, Nandini, Srinivas, Sujay, Vallathol, Dilip Harindran, Boppana, Mounika, Rajpurohit, Annu, Mahajan, Abhishek, Janu, Amit, Chatterjee, Abhishek, Krishnatry, Rahul, Gupta, Tejpal, Jalali, Rakesh, Patil, Vijay M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929766/
https://www.ncbi.nlm.nih.gov/pubmed/33680080
http://dx.doi.org/10.3332/ecancer.2021.1166